TKT and renal carcinoma: These observations indicate that PKM2 knockdown can abrogate TKT overexpression-induced cisplatin resistance, thereby supporting the notion that TKT participates in the modulation of cisplatin sensitivity in renal cancer cells through the regulation of PKM2.